ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients […]
Transaction advances Patria’s efforts to consolidate the region’s fragmented Real Estate market by adding a diversified and well-established platform in […]